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Editorial on the Research Topic
The Natural Killer Cell Interactome in the Tumor Microenvironment: Basic Concepts and
Clinical Application
NK cell activity is impaired in cancer patients, supporting the use of adoptive NK cell therapy,
which is becoming a credible immunotherapy for hematological malignancies. This is even more
so the case after the presentation of the first clinical study using anti-CD19 NK CAR cells, which
showed a good clinical activity in the absence of toxicity. The possibility of targeting solid tumors
is being studied by numerous laboratories, but the tumor microenvironment supports immune
suppression. Unveiling themolecular and cellular mechanisms explaining this immunosuppression
is a major goal.
For this special issue, we pointed to several specific subjects, such as the metabolic interactions
of NK cells with tumor targets that would regulate their function or novel molecular strategies
for generating off-the-shelf NK cell cancer immunotherapies. A total of 10 manuscripts have been
accepted for publication, of which five are original research and five are reviews or minireviews.
Regarding the original research articles, Alvarez et al. have described the indirect contribution
of the PD-1/PD-L1 system to the regulation of NK cell exhaustion using an in vivomurine model.
They showed that a PD-1 blockade increased CD8+ T cell activation rates, which competed for
IL-2 and resources with NK cells, retarding their activation but also their subsequent exhaustion.
Federici et al. developed an exhaustive work characterizing NK-cell derived extracellular vesicles
(NKEVs), separating true exosomes frommicrovesicles. They demonstrated that NKEVs supported
immune activation, modulating the expression of key stimulatory molecules in monocytes and in
T cells. They also demonstrated that the amount of NKEVs is reduced in the plasma of melanoma
patients compared with healthy donors. TheMartin Villalba’s group, in collaboration with clinicians
and the group of Alexia et al., investigated the antitumor effect of the new immunoadjuvant
Polyoxidonium (PO) in breast cancer patients. They demonstrate that PO increases activation
markers in dendritic cells, favoring T-cell activation. In addition, PO increased the degranulation
capacity of NK cells, showing positive clinical effects in a percentage of patients. Diaz et al.
performed an interesting clinical study on a cohort of 60 young and pediatric patients with
hematological malignancies. Patients were engrafted with haploidentical stem cells after T- and
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B-cell depletion. Improved outcomes correlated with a
rapid expansion of mature CD56dim NK cells early after
transplantation, suggesting a positive graft vs. leukemia effect.
Directly entering in the off-the-shelf NK cells for cancer
immunotherapy, Fernández et al. described the manufacturing
in GMP conditions of allogeneic NKG2D CAR T cells. To avoid
undesirable graft vs. host reactions, CD45− memory T cells were
used, and good expansions of active CAR T cells were obtained.
Regarding reviews, Nersesian et al. published a comprehensive
work describing the typical immunosuppressive tumor
microenvironment (TME) of ovarian tumors and how adoptive
NK cell treatment can help to revert this situation, alone or in
combination with other immunotherapies. In fact, at least nine
clinical trials using this approach in ovarian cancer patients are
currently ongoing. Terrén et al. put the point on the molecular
mechanisms that explain the inactivation of NK cell function
by the TME through the modulation of NK cell metabolism.
This review has attracted interest, being the most read paper
of the collection at the moment, with more than 6,000 views.
Villalba et al. describe strategies to improve NK cell anti-tumoral
function, including combination with mAbs to induce ADCC,
“arming” NK cells with antibodies, or the use of metabolic
drugs that could increase tumor sensitivity to activated NK
cells. Burger et al. described a promising field for NK cell-based
therapy; CAR NK cells would be used for the treatment of
glioblastoma, with the tumor antigen HER2 as the main target
at the moment. Finally, and in relation with the first original
article mentioned at the beginning of this editorial, Lanuza et al.
reviewed the available experimental evidences regarding the role
of immune checkpoints in NK cell function during physiological
and pathological (cancer) conditions, arriving at the conclusion
that the main checkpoint molecules targeted in T cells (CTLA-4,
PD-1, LAG-3) have low impact in NK cell function during
physiological conditions. This might be an additional advantage
when using adoptive allogeneic NK cell transfer in the treatment
of cancer.
As stated in the presentation of the special issue, we can
therefore consider that this collection of reviews and original
articles highlights significant advances made in the field of NK
cell-based therapy and indicate potential new useful directions,
always keeping in mind the benefit of patients and the
improvement of their quality of life.
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